Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517933 · ClinicalTrials.gov registry record · Phase 3
Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
NCT00517933 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 180 participants.
The verdict
NCT00517933, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
Study Summary
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication that increases blood flow to the lungs, at improving breathing function, exercise capacity, and quality of life in people with advanced IPF.
Interventions
- OTHER Placebo
- DRUG Sildenafil Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517933
The ClinicalTrials.gov registry entry for NCT00517933 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00517933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517933 about?
NCT00517933 is a clinical study titled "Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis". Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication that increases blood flow to the lungs, at improving breathing function, exercise capacity, and quality of life in peo...
What is the current status of trial NCT00517933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2007-08. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00517933?
The interventions under investigation include: Placebo (OTHER), Sildenafil Citrate (DRUG).
Who is sponsoring clinical trial NCT00517933?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.